Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Eur J Clin Pharmacol ; 68(5): 853-6, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22205276

RESUMO

PURPOSE: Long-term regular use of ketamine has been reported to be associated with severe symptomatic urinary tract problems. Methoxetamine, an arylcyclohexylamine derivative of ketamine, is marketed as a "bladder safe" derivative of ketamine, and no cases of acute toxicity following analytically confirmed methoxetamine use have been reported to date. We report here a case series of three individuals with acute toxicity related to the analytically confirmed use of methoxetamine. CASE SERIES: Three patients aged between 28 and 42 years presented to the Emergency Department (ED) on unrelated occasions having used methoxetamine. Clinical features were suggestive of a "dissociative/catatonic" state similar to that seen with ketamine; in addition, they had clinical features of acute sympathomimetic toxicity with significant tachycardia and hypertension. All were managed with low-dose benzodiazepines and discharged home once their symptoms/signs had settled. TOXICOLOGICAL SCREENING: Serum collected at the time of presentation to the ED was analysed qualitatively and quantitatively by gas chromatography-mass spectrometry. Serum concentrations ranged from 0.09 to 0.2 mg/L; in addition, detectable levels of 6-APB/5-APB were found in one of the patients. CONCLUSIONS: These three analytically confirmed cases demonstrate that acute methoxetamine-related toxicity is associated with both "dissociative" and "sympathomimetic" clinical features. The information from these three cases is useful to clinical pharmacologists, not only in managing individuals with acute methoxetamine toxicity but also in advising the appropriate legislative authorities on the risk of acute harm related to methoxetamine use. Further work is needed to determine whether methoxetamine is more "bladder friendly" than ketamine, as has been suggested by those marketing methoxetamine.


Assuntos
Cicloexanonas/toxicidade , Cicloexilaminas/toxicidade , Drogas Ilícitas/toxicidade , Síndromes Neurotóxicas/fisiopatologia , Administração por Inalação , Administração Oral , Adulto , Acatisia Induzida por Medicamentos/etiologia , Anticonvulsivantes/administração & dosagem , Anticonvulsivantes/uso terapêutico , Catatonia/etiologia , Confusão/etiologia , Cicloexanonas/administração & dosagem , Cicloexanonas/sangue , Cicloexilaminas/administração & dosagem , Cicloexilaminas/sangue , Tratamento de Emergência , Alucinações/etiologia , Humanos , Hipertensão/etiologia , Hipnóticos e Sedativos/administração & dosagem , Hipnóticos e Sedativos/uso terapêutico , Drogas Ilícitas/sangue , Masculino , Síndromes Neurotóxicas/tratamento farmacológico , Síndromes Neurotóxicas/terapia , Convulsões Febris/etiologia , Taquicardia/etiologia , Resultado do Tratamento
2.
Cancer Res ; 64(17): 6225-32, 2004 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-15342408

RESUMO

Hyperforin (Hyp), the major lipophilic constituent of St. John's wort, was assayed as a stable dicyclohexylammonium salt (Hyp-DCHA) for cytotoxicity and inhibition of matrix proteinases, tumor invasion, and metastasis. Hyp-DCHA triggered apoptosis-associated cytotoxic effect in both murine (C-26, B16-LU8, and TRAMP-C1) and human (HT-1080 and SK-N-BE) tumor cells; its effect varied, with B16-LU8, HT-1080, and C-26 the most sensitive (IC50 = 5 to 8 micromol/L). At these concentrations, a marked and progressive decline of growth was observed in HT-1080 cells, whereas untransformed endothelial cells were only marginally affected. Hyp-DCHA inhibited in a dose-dependent and noncompetitive manner various proteinases instrumental to extracellular matrix degradation; the activity of leukocyte elastase was inhibited the most (IC50 = 3 micromol/L), followed by cathepsin G and urokinase-type plasminogen activator, whereas that of the matrix metalloproteinases (MMPs) 2 and 9 showed an IC50 > 100 micromol/L. Nevertheless, inhibition of extracellular signal-regulated kinase 1/2 constitutive activity and reduction of MMP-2 and MMP-9 secretion was triggered by 0.5 micromol/L Hyp-DCHA to various degrees in different cell lines, the most in C-26. Inhibition of C-26 and HT-1080 cell chemoinvasion (80 and 54%, respectively) through reconstituted basement membrane was observed at these doses. Finally, in mice that received i.v. injections of C-26 or B16-LU8 cells, daily i.p. administration of Hyp-DCHA-without reaching tumor-cytotoxic blood levels-remarkably reduced inflammatory infiltration, neovascularization, lung weight (-48%), and size of experimental metastases with C-26 (-38%) and number of lung metastases with B16-LU8 (-22%), with preservation of apparently healthy and active behavior. These observations qualify Hyp-DCHA as an interesting lead compound to prevent and contrast cancer spread and metastatic growth.


Assuntos
Neoplasias/tratamento farmacológico , Terpenos/farmacologia , Adenocarcinoma/sangue , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/patologia , Animais , Apoptose/efeitos dos fármacos , Compostos Bicíclicos com Pontes , Divisão Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Neoplasias do Colo/sangue , Neoplasias do Colo/tratamento farmacológico , Neoplasias do Colo/patologia , Cicloexilaminas/sangue , Cicloexilaminas/farmacologia , Ativação Enzimática/efeitos dos fármacos , Fibrossarcoma/sangue , Fibrossarcoma/tratamento farmacológico , Fibrossarcoma/patologia , Gelatinases/biossíntese , Humanos , Neoplasias Pulmonares/sangue , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/secundário , Masculino , Melanoma Experimental/sangue , Melanoma Experimental/tratamento farmacológico , Melanoma Experimental/patologia , Camundongos , Camundongos Endogâmicos BALB C , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Proteína Quinase 3 Ativada por Mitógeno , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Invasividade Neoplásica , Metástase Neoplásica , Neoplasias/sangue , Neoplasias/patologia , Neuroblastoma/sangue , Neuroblastoma/tratamento farmacológico , Neuroblastoma/patologia , Floroglucinol/análogos & derivados , Compostos de Amônio Quaternário/sangue , Compostos de Amônio Quaternário/farmacologia , Serina Endopeptidases/metabolismo , Terpenos/sangue
3.
Toxicol Sci ; 53(1): 33-9, 2000 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-10653518

RESUMO

Twenty-one monkeys (cynomolgus, rhesus, African green) were fed cyclamate (100 mg/kg and 500 mg/kg) in the diet five times per week from a few days after birth and continuing for up to 24 years. Malignant tumors were diagnosed in three 24-year-old cyclamate monkeys; these were metastatic colon carcinoma (rhesus; 500 mg/kg), metastatic hepatocellular carcinoma (cynomolgus; 500 mg/kg), and a small, well differentiated adenocarcinoma of the prostate (cynomolgus; 100 mg/kg). Benign tumors were found at necropsy in three females; these were adenoma of the thyroid gland (rhesus; 100 mg/kg) and two cases of leiomyoma of the uterus (rhesus; 100 mg/kg and 500 mg/kg). No tumors were detected in an age-matched control group of 16 monkeys. Examination of the testes revealed complete testicular atrophy in one of the old cyclamate monkeys, and focal germ cell aplasia (Sertoli-only tubules) in two other cyclamate monkeys. Focal spermatogenic interruption (maturation arrest) at various germ cell levels mixed with normal spermatogenesis was observed in both the cyclamate-treated and the control monkeys, all of which were over 20 years old. Measurements of terminal cyclohexylamine concentrations showed that three of the males dosed with cyclamate at 500 mg/kg were high converters, with plasma concentrations comparable to the levels that produce testicular atrophy in rats. However, only one of the three high converters showed histologic evidence of irregular spermatogenesis. The overall conclusion is that the testicular abnormalities and the sporadic cases of different malignancies found after more than 20 years of dosing do not provide clear evidence of a toxic or carcinogenic effect of sodium cyclamate in monkeys.


Assuntos
Carcinógenos/toxicidade , Ciclamatos/toxicidade , Animais , Animais Recém-Nascidos , Atrofia/induzido quimicamente , Atrofia/patologia , Testes de Carcinogenicidade , Chlorocebus aethiops , Cicloexilaminas/sangue , Feminino , Estudos Longitudinais , Macaca fascicularis , Macaca mulatta , Masculino , Neoplasias Experimentais/etiologia , Ratos , Testículo/efeitos dos fármacos , Testículo/patologia
4.
J Chromatogr ; 573(2): 191-200, 1992 Jan 17.
Artigo em Inglês | MEDLINE | ID: mdl-1601951

RESUMO

A technique for sample work-up and enrichment using a supported liquid membrane in an automated flow system, connected to a gas chromatograph, was used for the determination of aliphatic amines in human blood plasma. The amines studied were N,N-dimethylethylamine, triethylamine, N-methylmorpholine, cyclohexylamine and N,N-dimethylcyclohexylamine. An efficient clean-up of the complex plasma matrix was achieved, resulting in identical blank chromatograms for plasma samples and aqueous solutions. Different parameters influencing the efficiency and selectivity of the extraction procedure were experimentally studied and theoretically explained. The detection limit depends on the extraction flow-rate and the available sample volume. With 1 ml of sample and a flow-rate giving an extraction time of 16 min, the detection limit was ca. 5 ppb (5 micrograms/l); with 4 ml of sample and a lower flow-rate, sub-ppb detection limits could be reached in ca. 3 h. Linear calibration curves up to 500 ppb were obtained. Blood plasma samples from volunteers exposed to N,N-dimethylethylamine in air were analysed, and the results compared favourably with independent measurements by another method.


Assuntos
Aminas/sangue , Cromatografia Gasosa , Cicloexilaminas/sangue , Etilaminas/sangue , Humanos , Membranas Artificiais , Morfolinas/sangue , Exposição Ocupacional
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA